Patient P-01712
Synthetic patientNBL-101 · Day 115 · 25–34 · F · baseline S13Steering view · 3DOpen companion preview
Therapy response
Declining
Tolerance
Improving
GI state
Deteriorating
Inflammatory state
Improving
Nutritional resilience
Favorable
Discontinuation risk
27%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S13
- Day 17 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 84 HY-01 recommended — Hydration Protocol HY-01
- Day 85 Patient accepted — Started HY-01 in the companion
- Day 89 No meaningful change — Hydration Protocol HY-01
What changed?
Trajectory began diverging from predicted response on Day 17.
Primary contributors, last 14 days
- Toxicity-11
- GI instability+8
- Inflammatory activity-8
- Treatment adherence+3
What helped?
- Hydration Protocol HY-01Day 84Result: no meaningful change
LIFE OS recommendation
No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
GI burden
Companion31.6/100
improving · -3.6 vs previous 14 d
Toxicity
Blood11.8/100
worsening · +5.6 vs previous 14 d
Sleep quality
Wearable22.4/100
improving · +1.6 vs previous 14 d
Energy level
Daily log5.5/10
stable · +0.1 vs previous 14 d
Stress level
Daily log3.8/10
stable · +0.1 vs previous 14 d
Steps
Wearable6,180
stable · -103 vs previous 14 d
Adherence
Companion94.7 %
stable · -2.3 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards failing · 69 from the failing basin, 21 from restoration.
Would help
- No untried action with strong evidence. Compose one from primitives.
Would not help
- HY-01 Hydration Protocolalready tried, no meaningful change
- Keep alcohol lowGI +3.7 next day on high-intake days · n 20
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Alcohol+3.7detractor · 95%
- Simple carbohydrates+1.8no signal · 47%
- Dietary fat load+1.2no signal · 30%
- Histamine load-0.4no signal · 15%
- Spicy / capsaicin-0.4no signal · 15%
- Insoluble fibre-0.3no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Autonomic recovery ↓45
- WearableResting HR 75 bpm
- WearableShort sleep window
- Mucosal barrier integrity ↓10
- WearableSleep 4.9 h, below personal baseline
DNA
Fictional pharmacogenomic panel
- CYP2D6 Normal metabolizerExpected exposure
Microbiome
Shannon diversity 3.2 · butyrate capacity 48/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisNormal
- Bifidobacterium longumNormal
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 49 ms
- Sleep
- 6.0 h
- Steps
- 6,859
- Resting HR
- 74 bpm
Daily log: GI score 32, nutritional resilience 62, adherence 95.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Keep fibre steady; no new sources this week
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Log the daily check-in; one line is enough
- Keep the current walking rhythm
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.